Leonard H Verhey1, Alessio Signori, Douglas L Arnold, Amit Bar-Or, A Dessa Sadovnick, Ruth Ann Marrie, Brenda Banwell, Maria Pia Sormani. 1. From the Pediatric Demyelinating Disease Program (L.H.V.), Program in Neuroscience & Mental Health, The Hospital for Sick Children, University of Toronto, Canada; Biostatistics Unit (A.S., M.P.S.), Department of Health Sciences, University of Genova, Italy; Department of Neurology & Neurosurgery (D.L.A., A.B.-O.), Montreal Neurological Institute and Hospital, McGill University, Montreal; Department of Neurology and Division of Medical Genetics (A.D.S.), University of British Columbia, Vancouver; Departments of Internal Medicine and Community Health Sciences (R.A.M.), Winnipeg Health Sciences Centre, University of Manitoba, Winnipeg, Canada; and Division of Neurology (B.B.), Department of Pediatrics, The Children's Hospital of Philadelphia, University of Pennsylvania.
Abstract
OBJECTIVE: To estimate sample sizes for pediatric multiple sclerosis (MS) trials using new T2 lesion count, annualized relapse rate (ARR), and time to first relapse (TTFR) endpoints. METHODS: Poisson and negative binomial models were fit to new T2 lesion and relapse count data, and negative binomial time-to-event and exponential models were fit to TTFR data of 42 children with MS enrolled in a national prospective cohort study. Simulations were performed by resampling from the best-fitting model of new T2 lesion count, number of relapses, or TTFR, under various assumptions of the effect size, trial duration, and model parameters. RESULTS: Assuming a 50% reduction in new T2 lesions over 6 months, 90 patients/arm are required, whereas 165 patients/arm are required for a 40% treatment effect. Sample sizes for 2-year trials using relapse-related endpoints are lower than that for 1-year trials. For 2-year trials and a conservative assumption of overdispersion (ϑ), sample sizes range from 70 patients/arm (using ARR) to 105 patients/arm (TTFR) for a 50% reduction in relapses, and 230 patients/arm (ARR) to 365 patients/arm (TTFR) for a 30% relapse reduction. Assuming a less conservative ϑ, 2-year trials using ARR require 45 patients/arm (60 patients/arm for TTFR) for a 50% reduction in relapses and 145 patients/arm (200 patients/arm for TTFR) for a 30% reduction. CONCLUSION: Six-month phase II trials using new T2 lesion count as an endpoint are feasible in the pediatric MS population; however, trials powered on ARR or TTFR will need to be 2 years in duration and will require multicentered collaboration.
OBJECTIVE: To estimate sample sizes for pediatric multiple sclerosis (MS) trials using new T2 lesion count, annualized relapse rate (ARR), and time to first relapse (TTFR) endpoints. METHODS: Poisson and negative binomial models were fit to new T2 lesion and relapse count data, and negative binomial time-to-event and exponential models were fit to TTFR data of 42 children with MS enrolled in a national prospective cohort study. Simulations were performed by resampling from the best-fitting model of new T2 lesion count, number of relapses, or TTFR, under various assumptions of the effect size, trial duration, and model parameters. RESULTS: Assuming a 50% reduction in new T2 lesions over 6 months, 90 patients/arm are required, whereas 165 patients/arm are required for a 40% treatment effect. Sample sizes for 2-year trials using relapse-related endpoints are lower than that for 1-year trials. For 2-year trials and a conservative assumption of overdispersion (ϑ), sample sizes range from 70 patients/arm (using ARR) to 105 patients/arm (TTFR) for a 50% reduction in relapses, and 230 patients/arm (ARR) to 365 patients/arm (TTFR) for a 30% relapse reduction. Assuming a less conservative ϑ, 2-year trials using ARR require 45 patients/arm (60 patients/arm for TTFR) for a 50% reduction in relapses and 145 patients/arm (200 patients/arm for TTFR) for a 30% reduction. CONCLUSION: Six-month phase II trials using new T2 lesion count as an endpoint are feasible in the pediatric MS population; however, trials powered on ARR or TTFR will need to be 2 years in duration and will require multicentered collaboration.
Authors: D H Miller; B G Weinshenker; M Filippi; B L Banwell; J A Cohen; M S Freedman; S L Galetta; M Hutchinson; R T Johnson; L Kappos; J Kira; F D Lublin; H F McFarland; X Montalban; H Panitch; J R Richert; S C Reingold; C H Polman Journal: Mult Scler Date: 2008-09-19 Impact factor: 6.312
Authors: Arnaud Charil; Tarek A Yousry; Marco Rovaris; Frederik Barkhof; Nicola De Stefano; Franz Fazekas; David H Miller; Xavier Montalban; Jack H Simon; Chris Polman; Massimo Filippi Journal: Lancet Neurol Date: 2006-10 Impact factor: 44.182
Authors: D H Miller; D Soon; K T Fernando; D G MacManus; G J Barker; T A Yousry; E Fisher; P W O'Connor; J T Phillips; C H Polman; L Kappos; M Hutchinson; E Havrdova; F D Lublin; G Giovannoni; A Wajgt; R Rudick; F Lynn; M A Panzara; A W Sandrock Journal: Neurology Date: 2007-04-24 Impact factor: 9.910
Authors: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock Journal: N Engl J Med Date: 2006-03-02 Impact factor: 91.245
Authors: Douglas L Arnold; Brenda Banwell; Amit Bar-Or; Angelo Ghezzi; Benjamin M Greenberg; Emmanuelle Waubant; Gavin Giovannoni; Jerry S Wolinsky; Jutta Gärtner; Kevin Rostásy; Lauren Krupp; Marc Tardieu; Wolfgang Brück; Tracy E Stites; Gregory L Pearce; Dieter A Häring; Martin Merschhemke; Tanuja Chitnis Journal: J Neurol Neurosurg Psychiatry Date: 2020-03-04 Impact factor: 10.154
Authors: Giulia Fadda; Robert A Brown; Roberta Magliozzi; Berengere Aubert-Broche; Julia O'Mahony; Russell T Shinohara; Brenda Banwell; Ruth Ann Marrie; E Ann Yeh; D Louis Collins; Douglas L Arnold; Amit Bar-Or Journal: Ann Neurol Date: 2019-02-20 Impact factor: 10.422